



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	08/734,592
Filing Date	October 22, 1996
First Named Inventor	Andrew Goodearl et al.
Title	Glial Mitogenic Factors, Their Pre
Art Unit	1647
Examiner Name	Stephen Gucker
Attorney Docket Number	1094-1-022/CIP4/D-B/C-A

I hereby appoint:

 Practitioners associated with the Customer Number:

23565

OR

 Practitioner(s) named below:

Name	Registration Number
	TECH CENTER 1600/2900

AUG 09 2004

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

 The address associated with the above-mentioned Customer Number:

OR

 The address associated with Customer Number:

23565

OR

<input type="checkbox"/>	Firm or Individual Name			
Address				
Address				
City		State	Zip	
Country				
Telephone		Fax		

I am the:

 Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Name	Jane Wasman, Esq., Executive Vice President		
Signature			
Date	7-21-04	Telephone	(914) 347-4300 x161

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

<input type="checkbox"/>	*Total of _____ forms are submitted.
--------------------------	--------------------------------------

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	08/734,592
Filing Date	October 22, 1996
First Named Inventor	Andrew Goodearl et al.
Art Unit	1647
Examiner Name	Stephen Gucker
Attorney Docket Number	1094-1-022CIP4/D-B/C-1

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners associated with the Customer Number:

Please change the correspondence address for the above-identified application to:

The address associated with  
Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
Address			
City		State	
Country			
Telephone		Fax	

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)


**SIGNATURE of Applicant or Assignee of Record**

Name	Jane Wasman, Esq., Executive Vice President		
Signature			
Date	7-21-04	Telephone	914-347-4300 x 161

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

\*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**STATEMENT UNDER 37 CFR 3.73(b)**Andrew Goodearl; Paul Stroobant; Luisa Minghetti; Michael Waterfield; Mark Marchionni;  
Applicant/Patent Owner: Maio S. Chen; Ian HilesApplication No./Patent No.: 08/734,592 Filed/Issue Date: October 22, 1996Entitled: GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USEACORDA THERAPEUTICS, INC. a Corporation(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or2.  an assignee of less than the entire right, title and interest.The extent (by percentage) of its ownership interest is 50 %  
in the patent application/patent identified above by virtue of either:A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.**OR**B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: Andrew Goodearl, Paul Stroobant, Luisa Minghetti To: Ludwig Institute for Cancer ResearchThe document was recorded in the United States Patent and Trademark Office at Reel 6556, Frame 0263, or for which a copy thereof is attached.2. From: Mark Marchionni and Maio Su Chen To: Cambridge NeuroScienceThe document was recorded in the United States Patent and Trademark Office at Reel 6556, Frame 0262, or for which a copy thereof is attached.3. From: Cambridge NeuroScience To: Cenes Pharmaceuticals, IncThe document was recorded in the United States Patent and Trademark Office at Reel 011812, Frame 0784, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

7-21-04

Jane Wasman, Esq., Executive Vice President

Date  
(914) 347-4300 x161Re: 7-21-04

Typed or printed name

Jane Wasman

Telephone number

Signature

Ex. Vice President / General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments and suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



00200R

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

AUGUST 06, 2001

PTAS



\*101730121A\*

CLARK & ELBING, LLP  
KRISTINA BIEKER-BRADY, PH.D.  
176 FEDERAL STREET  
BOSTON, MA 02110

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/21/2001

REEL/FRAME: 011812/0784  
NUMBER OF PAGES: 3

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:  
CAMBRIDGE NEUROSCIENCE, INC.

DOC DATE: 01/18/2001

ASSIGNEE:  
CENES PHARMACEUTICALS, INC.  
333 PROVIDENCE HIGHWAY  
NORWOOD, MASSACHUSETTS 02062

SERIAL NUMBER: 08469549  
PATENT NUMBER:FILING DATE: 06/06/1995  
ISSUE DATE:SERIAL NUMBER: 08471833  
PATENT NUMBER:FILING DATE: 06/06/1995  
ISSUE DATE:SERIAL NUMBER: 08472065  
PATENT NUMBER:FILING DATE: 06/06/1995  
ISSUE DATE:SERIAL NUMBER: 08734665  
PATENT NUMBER:FILING DATE: 10/22/1996  
ISSUE DATE:

SERIAL NUMBER: 08735010	FILING DATE: 10/22/1996
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08736070	FILING DATE: 10/22/1996
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08736019	FILING DATE: 10/22/1996
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08734592	FILING DATE: 10/22/1996
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09493799	FILING DATE: 01/28/2000
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08209204	FILING DATE: 03/08/1994
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08461097	FILING DATE: 06/05/1995
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08467602	FILING DATE: 06/06/1995
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08468731	FILING DATE: 06/06/1995
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09525492	FILING DATE: 03/15/2000
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09069784	FILING DATE: 04/29/1998
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09366886	FILING DATE: 08/04/1999
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09298121	FILING DATE: 04/23/1999
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 09530884	FILING DATE: 08/29/2000
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08411295	FILING DATE: 03/27/1995
PATENT NUMBER:	ISSUE DATE:
SERIAL NUMBER: 08036555	FILING DATE: 03/24/1993
PATENT NUMBER: 5530109	ISSUE DATE: 06/25/1996
SERIAL NUMBER: 08249322	FILING DATE: 05/26/1994
PATENT NUMBER: 5716930	ISSUE DATE: 02/10/1998
SERIAL NUMBER: 08471855	FILING DATE: 06/06/1995
PATENT NUMBER: 5621081	ISSUE DATE: 04/15/1997

SERIAL NUMBER: 08469569  
PATENT NUMBER: 5606032

FILING DATE: 06/06/1995  
ISSUE DATE: 02/25/1997

SERIAL NUMBER: 08469526  
PATENT NUMBER: 5792849

FILING DATE: 06/06/1995  
ISSUE DATE: 08/11/1998

SERIAL NUMBER: 08470335  
PATENT NUMBER: 6147190

FILING DATE: 06/06/1995  
ISSUE DATE: 11/14/2000

SERIAL NUMBER: 08472008  
PATENT NUMBER: 5602096

FILING DATE: 06/06/1995  
ISSUE DATE: 02/11/1997

SERIAL NUMBER: 08734664  
PATENT NUMBER: 6204241

FILING DATE: 10/22/1996  
ISSUE DATE: 03/20/2001

SERIAL NUMBER: 08735021  
PATENT NUMBER: 6194377

FILING DATE: 10/22/1996  
ISSUE DATE: 02/27/2001

SERIAL NUMBER: 08734591  
PATENT NUMBER: 5854220

FILING DATE: 10/22/1996  
ISSUE DATE: 12/29/1998

SERIAL NUMBER: 07654104  
PATENT NUMBER: 5312928

FILING DATE: 02/11/1991  
ISSUE DATE: 05/17/1994

SERIAL NUMBER: 07854496  
PATENT NUMBER: 5298657

FILING DATE: 03/20/1992  
ISSUE DATE: 03/29/1994

SERIAL NUMBER: 08192990  
PATENT NUMBER: 5489709

FILING DATE: 02/08/1994  
ISSUE DATE: 02/06/1996

SERIAL NUMBER: 08469660  
PATENT NUMBER: 5876973

FILING DATE: 06/06/1995  
ISSUE DATE: 03/02/1999

SERIAL NUMBER: 08293465  
PATENT NUMBER: 5681568

FILING DATE: 08/19/1994  
ISSUE DATE: 10/28/1997

SERIAL NUMBER: 08341018  
PATENT NUMBER: 6087323

FILING DATE: 11/17/1994  
ISSUE DATE: 07/11/2000

SERIAL NUMBER: 08311365  
PATENT NUMBER: 5594114

FILING DATE: 09/23/1994  
ISSUE DATE: 01/14/1997

SERIAL NUMBER: 08470339  
PATENT NUMBER: 6232286

FILING DATE: 06/06/1995  
ISSUE DATE: 05/15/2001

05-24-2001

AUG 02 2004

JC24 EPU



Substitute Form PTO-1595

101730121

Attorney Docket Numbers: 04585/  
00200E, 00200F, 00200H, 00200I, 00200M, 00200N, 00200Q, 00200R, 00200S, 028001, 028002, 028003, 028004,  
028006, 041004, 041005, 044001, 048002, 039001, 002005, 002006, 002007, 002009, 00200A, 00200B, 00200G,  
00200J, 00200L, 00200P, 003001, 011001, 011002, 017009, 040001, 041001, 051001, 002008Certificate of Mailing: Date of Deposit May 17, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to BOX ASSIGNMENT, Commissioner, United States Patent and Trademark Office, Washington, D.C. 20231.

Julie A. Brown  
Printed Name of Person Mailing CorrespondenceJulie A. Brown  
Signature of Person Mailing CorrespondenceRECORDATION FORM COVER SHEET  
PATENTS ONLYS-21-01  
Please record the attached document.

1. Previous name of assignee:  Cambridge NeuroScience, Inc.	2. Current name and address of assignee:  CeNeS Pharmaceuticals, Inc. 333 Providence Highway Norwood, MA 02062
Additional names attached: NO	Additional names/addresses attached: NO
3. Nature of conveyance:  [ ] Assignment [ ] Merger [ ] Security Agreement [X] Change of Name [ ] Other: _____	40 E
Execution Date: January 18, 2001	
4. Application numbers or patent numbers:  A. Patent Application Numbers: — 08/469,549 — 08/471,833 08/472,065 08/734,865 08/735,010 08/738,070 08/738,019 08/734,592 09/493,799 08/209,204 08/461,097 08/467,602 08/468,731 09/525,492 09/069,784 09/366,886 09/298,121 09/530,884 08/411,295	B. Patent Numbers:  5,530,109 5,716,930 5,621,081 5,806,032 5,792,849 6,147,190 5,602,096 6,204,241 6,194,377 5,854,220 5,312,928 5,298,657 5,489,709 5,876,973 5,681,568 6,087,323 5,594,114 6,232,286

AUG 09 2004  
TECH CENTER 1600/2806

5. Name and address of party to whom correspondence concerning document should be mailed:

Kristina Bieker-Brady, Ph.D., Reg. No. 39,109  
Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Customer No.: 21559

6. Total number of applications/patents involved: 37

7. Total fee (37 C.F.R. § 3.41): \$1,480

Fee enclosed


Authorized to charge deposit account


8. Deposit account number: 03-2095. If the fee above is being charged to deposit account, a duplicate copy of this cover sheet is attached. Please apply any additional charges, or any credits, to Deposit Account No. 03-2095.

DO NOT USE THIS SPACE

9. Statement and signature: *To the best of my knowledge and belief, the foregoing information is true and correct and the attached is the original document.*

Kristina Bieker-Brady, Ph.D.  
Name of person signing

  
Signature

  
Date



21559

PATENT TRADEMARK OFFICE

State of Delaware  
Office of the Secretary of State

PAGE 1

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "CAMBRIDGE NEUROSCIENCE, INC.", CHANGING ITS NAME FROM "CAMBRIDGE NEUROSCIENCE, INC." TO "CENTES PHARMACEUTICALS, INC.", FILED IN THIS OFFICE ON THE EIGHTEENTH DAY OF JANUARY, A.D. 2001, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

*Harriet Smith Windsor*


Secretary of State

AUTHENTICATION: 0922053

DATE: 01-18-01

2078819 8100

010028302





PATENT

ATTORNEY DOCKET NOS. 04585/

00200E, 00200F, 00200H, 00200I, 00200M, 00200N, 00200Q, 00200R, 00200S, 028001, 028002, 028003, 028004, 028006, 041004, 041005, 044001, 048002, 039001, 002005, 002006, 002007, 002009, 00200A, 00200B, 00200G, 00200J, 00200L, 00200P, 003001, 011001, 011002, 017009, 046001, 041001, 051001, 002008

Certificate of Mailing: Date of Deposit: May 17, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Julie A. Bowen

Printed name of person mailing correspondence

Julie A. Bowen

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Conveying Party: Cambridge Neuroscience, Inc.

Receiving Party: CeNeS Pharmaceuticals, Inc.

Execution Date: January 18, 2001

Customer No.: 21559

Patent Nos.: 5,530,109; 5,716,930; 5,621,081;  
5,606,032; 5,792,849; 6,147,190;  
5,602,096; 6,204,241; 6,194,377;  
5,854,220; 5,312,928; 5,298,657;  
5,489,709; 5,876,973; 5,681,568;  
6,087,323; 5,594,114; 6,232,286

AUG 09 2004

TECH CENTER 1600/2900

Serial Nos.: 08/469,549; 08/471,833; 08/472,065;  
08/734,665; 08/735,010; 08/736,070;  
08/736,019; 08/734,592; 09/493,799;  
08/209,204; 08/461,097; 08/467,602;  
08/468,731; 09/525,492; 09/069,784;  
09/366,886; 09/298,121; 09/530,884;  
08/411,295

Assignment Branch

Assistant Commissioner For Patents

Washington, D.C. 20231


SUBMISSION OF NAME CHANGE

Effective immediately, please change the name on all assignments as indicated on  
the attached Recordation Form Cover Sheet.

We are enclosing official document executed by the Secretary of State, State of Delaware, specifying the name change.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,



*Kristina Bicker-Brady*

Date: May 17, 2001

Kristina Bicker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



04585.001001 Submission of Name Change.wpd

ASSIGNMENT OF INVENTION

In consideration of the payment by ASIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR: CeNeS Pharmaceuticals plc  
Compass House, Vision Park  
Chivers Way, Histon  
Cambridge CB4 9ZR  
UK

(If assignment is by person or entity to whom invention was previously assigned and this was recorded in PTO add the following)

Recorded on: \_\_\_\_\_

Reel: \_\_\_\_\_

Frame: \_\_\_\_\_

Hereby sell, assign and transfer to

ASSIGNEE: Acorda Therapeutics, Inc.  
15 Skyline Drive  
Hawthorne, New York 10532  
U.S.A.

And the successors, assigns and legal representatives of the ASIGNEE the entire right, title and interest, including the right to sue for present, past and future infringement, in the United States, its territorial possessions, and in all foreign countries, including all treaty and convention rights in and to the invention and any and all improvements of the patents and patent applications listed on Schedule A attached hereto;

And any legal equivalent thereof in a foreign country, and, in and to, all United States and foreign Letters Patent, for the full term thereof, to be obtained for said invention by the above application or any continuation, division, renewal, extension or substitute thereof, and as to letters patents any re-issue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all such Letters Patent to ASSIGNEE:


ASSIGNOR further covenants to promptly provide all pertinent facts and documents known and accessible to ASSIGNOR relating to said invention and said Letters Patent and legal equivalents; to testify as to the same in any interference, litigation or proceeding related thereto; to execute and deliver any and all papers that may be necessary or desirable to perfect the title to said invention or any Letters Patents which may be granted therefore in said ASSIGNEE, its

successors, assigns or other legal representatives; to execute any additional or divisional applications for patents for said invention or any part or parts thereof, and for the reissue of any Letters Patents to be granted therefore; and to make all rightful oaths and do all lawful acts requisite for procuring the same or for aiding therein, all without further compensation, but at the sole expense of ASSIGNEE, its successors, assigns, or other legal representatives.

ASSIGNORS hereby grants ASSIGNEE and Assignee's attorneys the power to insert the Serial No. and/or filing date of the above-described application(s) after such information becomes known to them.

IN WITNESS WHEREOF, I have hereunto set hand and seal.

ASSIGNOR:



Dated: 28-02-07

SCHEDULE A

U.S. Patent No.	Issue Date	Title	Inventor(s)
5,530,109	06/25/1996	DNA ENCODING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
5,602,096	02/11/1997	METHOD OF USING A SECRETABLE GLIAL MITOGENIC FACTOR TO INDUCE ACETYLCHOLINE RECEPTOR SYNTHESIS	A. Goodearl et al.
6,147,190	11/14/2000	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,854,220	12/29/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,792,849	08/11/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,621,081	04/15/1997	GLIAL MITOGENIC FACTORS	A. Goodearl et al.
5,606,032	03/28/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
6,232,286	06/16/2001	METHOD OF PREPARING NITROGENOUS GLIAL CELLS USING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
6,194,377	02/27/2001	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,716,930	02/10/1998	GLIAL MITOGENIC FACTORS	A. Goodearl et al.
6,204,241	03/20/2001	METHOD OF PREPARING GLIAL CELLS	A. Goodearl et al.
6,444,642	09/03/2002	METHOD OF PREPARING GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE ON SURFACE OF MUSCLE CELL FOR INDUCING DIFFERENTIATION OF MUSCLE CELLS BY MANGULIN	Robert Sklar et al.
5,594,114	01/16/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
6,087,323	07/11/2000	USE OF TETRACOLINE AS MODULATORS OF CELLULAR COMMUNICATION	David Gwynne et al.
5,876,973	03/02/1999	REFINED FOR RAISING ANTIBODIES WHICH SPECIFICALLY BIND TO GLIAL GROWTH FACTORS	David Gwynne et al.

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
08/671,833	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/730,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/736,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,392	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/736,070	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/472,065	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/735,010	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/469,549	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,665	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.

SCHEDULE A (Continued)

U.S. Patent Application No.	Filing Date	Title	Invantor(s)
08/461,097	06/05/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/468,731	06/06/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/411,295	03/27/1995	METHOD FOR TREATING DISORDERS OF THE EYE	T.A. Reh ET AL.
09/069,784	03/20/2001	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. Gwynne ET AL.
09/366,886	08/04/1999	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. Gwynne ET AL.
09/298,121	04/23/1999	METHOD FOR TREATING CONGESTIVE HEART FAILURE	K. BIEKER-BRADY ET AL.
09/530,884	10/18/1998	ATHERAPEUTICS METHODS COMPRISING USE OF A NEUREGULIN	R.H. McDURNIN ET AL.